H.C. Wainwright analyst, Corey Davis, reiterated his Buy rating on shares of Aldeyra Therapeutics (NASDAQ: ALDX) on the belief that ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE